Infinium Pharmachem Share PriceInfinium Pharmachem

₹264.1
-13.9 (-5%)
As on 01 October, 2023 | 20:39 BSE: NSE: INFINIUMISIN: INE0MRE01011

Infinium Pharmachem Performance

Day Range

  • Low 264.1
  • High 264.2
264.1

52 Week Range

  • Low 70.75
  • High 315.7
264.1
  • Open Price264.1
  • Previous Close278
  • Volume34000

Start SIP in Infinium Pharmachem

Start SIP

Infinium Pharmachem Share Price

  • Over 1 Month 0.23%
  • Over 3 Month 90.34%

Infinium Pharmachem Key Statistics

P/E Ratio
PEG Ratio
Market Cap Cr 368
Price to Book Ratio 15.5
EPS 6.6
Dividend 0
Relative Strength Index 49.39
Money Flow Index 52.65
MACD Signal 18.31
Average True Range 14.13

Infinium Pharmachem Investment Rating

  • Master Rating:
  • Infinium Pharmachem Ltd has an operating revenue of Rs. 322.72 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 11% is healthy, ROE of 42% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 12% and 51% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 97 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 2 indicates it belongs to a strong industry group of Comml Svcs-Healthcare and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Infinium Pharmachem Financials
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 10375
Operating Expenses Annual Cr 8665
Operating Profit Annual in Cr 159
Depreciation Cr 11
Interest Annual Cr 32
Tax Annual Cr 32
Net Profit Annual Cr 96
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 9
Cash from Investing Activity Annual Cr -7
Cash from Financing Annual Activity Cr -2
Net Cash Flow Annual Cr 0
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 2213
Fixed Assets Annual Cr 1612
Total Non Current Assets Annual Cr 1615
Total Current Assets Annual Cr 4434
Total Assets Annual Cr 6049
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 43123
ROE Annual % 4244
ROCE Annual % 5235
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1613
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 116100
Operating Expenses Annual Cr 9889
Operating Profit Annual in Cr 1610
Depreciation Cr 11
Interest Annual Cr 32
Tax Annual Cr 32
Net Profit Annual Cr 96
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 12
Cash from Investing Activity Annual Cr -7
Cash from Financing Annual Activity Cr -2
Net Cash Flow Annual Cr 3
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 2314
Fixed Assets Annual Cr 1913
Total Non Current Assets Annual Cr 1915
Total Current Assets Annual Cr 5144
Total Assets Annual Cr 7159
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 47137
ROE Annual % 4244
ROCE Annual % 4738
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1511

Infinium Pharmachem Technicals

EMA & SMA

Current Price
₹264.1
-13.9 (-5%)
  • Bullish Moving Average
  • ___
  • 4
  • Bearish Moving Average
  • ___
  • 9
  • 20 Day
  • ₹274.03
  • 50 Day
  • ₹239.58
  • 100 Day
  • ₹190.4
  • 200 Day
  • 20 Day
  • ₹272.93
  • 50 Day
  • ₹234.43
  • 100 Day
  • ₹186.51
  • 200 Day

Infinium Pharmachem Resistance and Support

PIVOT
₹264.14
Resistance
First Resistance ₹264.17
Second Resistance ₹264.24
Third Resistance ₹264.27
RSI 49.39
MFI 52.65
MACD Single Line 18.31
MACD 14.96
Support
First Resistance ₹264.07
Second Resistance ₹264.04
Third Resistance ₹263.97

Infinium Pharmachem Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 34,000 3,200,080 94.12
Week 14,800 1,359,972 91.89
1 Month 11,286 1,014,247 89.87
6 Month 28,661 2,387,772 83.31

Infinium Pharmachem Result Highlights

Infinium Pharmachem Synopsis

NSE-Comml Svcs-Healthcare

Infinium Pharmachem belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 101.31 Cr. and Equity Capital is Rs. 5.08 Cr. for the Year ended 31/03/2023. Infinium Pharmachem Ltd. is a Public Limited Listed company incorporated on 21/11/2003 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24231GJ2003PLC043218 and registration number is 043218.
Market Cap 368
Sales 101
Shares in Float 1.39
No of funds
Yield
Book Value 12.37
U/D Vol ratio 1.5
LTDebt / Equity
Alpha 1.35
Beta -1.33

Infinium Pharmachem

Owner Name

Infinium Pharmachem Management

Name Designation
Mr. Sanjaykumar Viththalbhai Patel Chairman & Managing Director
Mr. Pravin Bhadabhai Madhani Executive Director
Mr. Mitesh Lavjibhai Chikhaliya Executive Director
Mr. Keyur Jagdishchandra Shah Independent Director
Mr. Tarun Ratilal Dobariya Independent Director
Mr. Vaishakhi Ambrishbhai Shukla Independent Director

Infinium Pharmachem Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Infinium Pharmachem Corporate Action

Date Purpose Remarks
2023-08-02 Bonus issue
2023-05-17 Audited Results
Date Purpose Remarks
2023-09-13 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.
  • Company Name
  • CMP
  • Chg(%)
  • Company Name
  • CMP
  • Chg(%)

Infinium Pharmachem FAQs

What is Share Price of Infinium Pharmachem ?

Infinium Pharmachem share price is ₹264 As on 01 October, 2023 | 20:25

What is the Market Cap of Infinium Pharmachem ?

The Market Cap of Infinium Pharmachem is ₹367.5 Cr As on 01 October, 2023 | 20:25

What is the P/E ratio of Infinium Pharmachem ?

The P/E ratio of Infinium Pharmachem is As on 01 October, 2023 | 20:25

What is the PB ratio of Infinium Pharmachem ?

The PB ratio of Infinium Pharmachem is 15.5 As on 01 October, 2023 | 20:25

Q2FY23